<DOC>
	<DOCNO>NCT02339584</DOCNO>
	<brief_summary>The purpose study compare fix combination ( BID ) [ Brinzolamide 10 mg/mL / Brimonidine 2 mg/mL eye drop , suspension ] unfixed combination ( BID ) [ Brinzolamide 10 mg/mL eye drop , suspension plus Brimonidine 2 mg/mL eye drop , solution ] respect intraocular pressure ( IOP ) -lowering efficacy . This study take place China , Taiwan , Russia .</brief_summary>
	<brief_title>Efficacy Safety Brinzolamide/Brimonidine Fixed Combination BID Compared Brinzolamide BID Plus Brimonidine BID Subjects With Open-Angle Glaucoma ( OAG ) Ocular Hypertension ( OHT )</brief_title>
	<detailed_description>This study divide 2 phase conduct sequence total 6 visit : Phase I ( Screening/Eligibility ) include Screening Visit , follow 2 Eligibility Visits ( E1 E2 ) Phase II ( Treatment/Follow-up ) include 3 visit Week 2 , Week 6 , Month 3 . Following washout IOP-lowering medication , subject meet inclusion/exclusion criterion Eligibility visit IOP measurement within specified range period randomize Phase II .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Brimonidine Tartrate</mesh_term>
	<mesh_term>Brinzolamide</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<criteria>Diagnosis openangle glaucoma ocular hypertension insufficiently control monotherapy currently multiple IOPlowering medication ; Mean IOP measurement within guideline specify protocol . Must &gt; 36 mmHg time point ; Able understand sign inform consent form ; Other protocolspecified inclusion criterion may apply . Women childbearing potential pregnant , test positive pregnancy , intend become pregnant study period , breastfeeding , agreement use adequate birth control method throughout study ; Severe central visual field loss either eye ; Unable safely discontinue IOPlowering ocular medication ( ) minimum 5 ( ± 1 ) 28 ( ± 1 ) day prior E1 Visit ; Chronic , recurrent severe inflammatory eye disease ; Ocular trauma within past 6 month ; Ocular infection ocular inflammation within past 3 month ; Clinically significant progressive retinal disease retinal degeneration , diabetic retinopathy , retinal detachment ; Bestcorrected visual acuity ( BCVA ) score bad 55 ETDRS letter ( equivalent approximately 0.60 logMAR , 20/80 Snellen , 0.25 decimal ) ; Other ocular pathology ( include severe dry eye ) may preclude administration αadrenergic agonist and/or topical carbonic anhydrase inhibitor ( CAI ) ; Intraocular surgery within past 6 month ; Ocular laser surgery within past 3 month ; Any abnormality prevent reliable applanation tonometry ; Any condition include severe illness would make Subject , opinion Investigator , unsuitable study ; History active , severe , unstable uncontrolled cardiovascular , cerebrovascular , hepatic , renal disease would preclude safe administration topical αadrenergic agonist CAI ; Recent ( within 4 week E1 Visit ) use highdose ( &gt; 1 g daily ) salicylate therapy ; Current anticipate treatment psychotropic drug augment adrenergic response ( eg , desipramine , amitriptyline ) ; Concurrent use monoamine oxidase inhibitor ( MAOI ) ; Concurrent use glucocorticoid administer route ; Therapy another investigational agent within 30 day prior Screening Visit ; Hypersensitivity αadrenergic agonist drug , topical oral CAIs , sulfonamide derivative , component study medication ; Less 30 day stable dose regimen Screening Visit medication ( exclude IOPlowering treatment ) substance administer route use chronic basis may affect IOP , include limited βadrenergic block agent ; Use additional topical systemic ocular hypotensive medication study ; Other protocolspecified exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>95 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>OAG</keyword>
	<keyword>OHT</keyword>
</DOC>